The US Food and Drug Administration grants Eli Lilly full approval for Inluriyo in combination with Verzenio for certain breast cancer patients. The approval covers use as a combination therapy rather than an interim authorization, according to reporting from Seeking Alpha and Business Line.
The treatment is described as the Inluriyo–Verzenio combination and is intended for patients with estrogen receptor-positive tumors. The outlets frame the decision as expanding Lilly’s regulatory standing for the regimen within that patient group, with both focusing on the same overall indication and drug combination.
While the two sources differ in emphasis—one foregrounds the “full FDA approval” wording and the other leads with the approval announcement—they align on the core facts: the FDA approves Lilly’s breast cancer drug combination and the regimen is for estrogen receptor-positive disease.
